Company: CERO
Filing Date: 2025-10-23
Form Type: 424B3
Source: 0001213900-25-101651
Chunk: 4

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-10-23
Form: 424B3
Chunk 4
---
 Act (17 CFR 230.425)                  |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)                 |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class                                                             |     | Trading Symbol(s) |     | Name of each exchange on which registered |
| Common stock, par value $0.0001 per share                                       |     | CERO              |     | Nasdaq Capital Market                     |
| Warrants, each warrant exercisable for one two-thousandth share of Common Stock |     | CEROW             |     | Nasdaq Capital Market                     |

Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☒

If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

Private Placement

Securities Purchase Agreement

On October 14, 2025, CERo Therapeutics
Holdings, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the
“Securities Purchase Agreement”) with certain accredited investors named therein (the “PIPE Investors”). Pursuant to the Securities Purchase Agreement, up to 9,750 shares of the Company’s Series E convertible
preferred stock, par value $0.0001 per share (the “Series E Preferred Stock”) shall be purchased for an aggregate
purchase price of up to $7 million in one or more closings (each a “Closing”), including approximately $1.8
million to be funded at the first closing. The date of the first closing is referred to as the “First Closing Date.” Each additional closing under the Securities Purchase Agreement is subject to a